Tagarakis 2013.

Methods	Study design: parallel‐group trial Duration of follow‐up: not reported Method of randomisation: not described Method of concealment of allocation: not described Blinding: single‐blind (outcome assessors) Power calculation: not mentioned Phases of the study: 1 (treatment phase)
Participants	Country of enrolment: Greece Setting/location: inpatient Diagnostic criteria (stable angina pectoris): not described Comorbidities: patients scheduled for elective on‐pump CABG Inclusion criteria: not described Exclusion criteria: not described
Interventions	Number of intervention groups: 2 Concomitant medications: not described Excluded medications: not described Control group Intervention: no treatment Duration of intervention: not reported Ranolazine group Intervention: ranolazine (type of formulation not specified) 375 mg twice daily for 3 days prior to surgery and until discharge Duration of intervention: not reported
Outcomes	Total number of outcomes: 3 (post‐operative atrial fibrillation, left atrial diameter, left ventricular ejection fraction) OUTCOMES No outcome meets the inclusion criteria
Notes